vs
CAMDEN NATIONAL CORP（CAC）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
CAMDEN NATIONAL CORP的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.8倍（$64.3M vs $35.5M），CAMDEN NATIONAL CORP净利率更高（34.0% vs -304.2%，领先338.3%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 22.6%）
卡姆登国民银行是一家总部位于美国缅因州卡姆登的商业银行，是上市银行控股公司卡姆登国民集团的核心子公司。该行创立于1875年，1984年完成企业重组后成为控股公司直接持有的全资子公司。2025年与诺斯韦金融合并后，合并后机构总资产约为70亿美元。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
CAC vs RXRX — 直观对比
营收规模更大
CAC
是对方的1.8倍
$35.5M
净利率更高
CAC
高出338.3%
-304.2%
两年增速更快
RXRX
近两年复合增速
22.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $64.3M | $35.5M |
| 净利润 | $21.9M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | — | -304.8% |
| 净利率 | 34.0% | -304.2% |
| 营收同比 | — | 681.7% |
| 净利润同比 | — | 39.6% |
| 每股收益（稀释后） | $1.29 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CACRXRX
| Q1 26 | $64.3M | — | ||
| Q4 25 | $68.1M | $35.5M | ||
| Q3 25 | $65.4M | $5.2M | ||
| Q2 25 | $62.3M | $19.2M | ||
| Q1 25 | $60.1M | $14.7M | ||
| Q4 24 | $47.6M | $4.5M | ||
| Q3 24 | $45.0M | $26.1M | ||
| Q2 24 | $42.8M | $14.4M |
净利润CACRXRX
| Q1 26 | $21.9M | — | ||
| Q4 25 | $22.6M | $-108.1M | ||
| Q3 25 | $21.2M | $-162.3M | ||
| Q2 25 | $14.1M | $-171.9M | ||
| Q1 25 | $7.3M | $-202.5M | ||
| Q4 24 | $14.7M | $-178.9M | ||
| Q3 24 | $13.1M | $-95.8M | ||
| Q2 24 | $12.0M | $-97.5M |
毛利率CACRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% |
营业利润率CACRXRX
| Q1 26 | — | — | ||
| Q4 25 | 41.5% | -304.8% | ||
| Q3 25 | 40.5% | -3327.6% | ||
| Q2 25 | 28.5% | -916.8% | ||
| Q1 25 | 10.3% | -1297.9% | ||
| Q4 24 | 38.7% | -4042.4% | ||
| Q3 24 | 35.2% | -377.1% | ||
| Q2 24 | 34.7% | -697.4% |
净利率CACRXRX
| Q1 26 | 34.0% | — | ||
| Q4 25 | 33.1% | -304.2% | ||
| Q3 25 | 32.4% | -3135.3% | ||
| Q2 25 | 22.6% | -894.2% | ||
| Q1 25 | 12.2% | -1373.3% | ||
| Q4 24 | 30.8% | -3935.5% | ||
| Q3 24 | 29.1% | -367.5% | ||
| Q2 24 | 28.0% | -676.6% |
每股收益（稀释后）CACRXRX
| Q1 26 | $1.29 | — | ||
| Q4 25 | $1.33 | $-0.17 | ||
| Q3 25 | $1.25 | $-0.36 | ||
| Q2 25 | $0.83 | $-0.41 | ||
| Q1 25 | $0.43 | $-0.50 | ||
| Q4 24 | $1.00 | $-0.56 | ||
| Q3 24 | $0.90 | $-0.34 | ||
| Q2 24 | $0.81 | $-0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $743.3M |
| 总债务越低越好 | $514.4M | $9.6M |
| 股东权益账面价值 | $710.0M | $1.1B |
| 总资产 | $7.0B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.72× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资CACRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | $743.3M | ||
| Q3 25 | — | $659.8M | ||
| Q2 25 | — | $525.1M | ||
| Q1 25 | — | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | — | $474.3M |
总债务CACRXRX
| Q1 26 | $514.4M | — | ||
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M |
股东权益CACRXRX
| Q1 26 | $710.0M | — | ||
| Q4 25 | $696.6M | $1.1B | ||
| Q3 25 | $676.4M | $1.0B | ||
| Q2 25 | $652.1M | $919.1M | ||
| Q1 25 | $640.1M | $933.9M | ||
| Q4 24 | $531.2M | $1.0B | ||
| Q3 24 | $529.9M | $524.6M | ||
| Q2 24 | $508.3M | $584.4M |
总资产CACRXRX
| Q1 26 | $7.0B | — | ||
| Q4 25 | $7.0B | $1.5B | ||
| Q3 25 | $7.0B | $1.4B | ||
| Q2 25 | $6.9B | $1.3B | ||
| Q1 25 | $7.0B | $1.3B | ||
| Q4 24 | $5.8B | $1.4B | ||
| Q3 24 | $5.7B | $726.5M | ||
| Q2 24 | $5.7B | $775.9M |
负债/权益比CACRXRX
| Q1 26 | 0.72× | — | ||
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流CACRXRX
| Q1 26 | — | — | ||
| Q4 25 | $63.9M | $-46.1M | ||
| Q3 25 | $36.1M | $-117.4M | ||
| Q2 25 | $6.0M | $-76.4M | ||
| Q1 25 | $1.0M | $-132.0M | ||
| Q4 24 | $60.9M | $-115.4M | ||
| Q3 24 | $-14.5M | $-59.2M | ||
| Q2 24 | $14.5M | $-82.2M |
自由现金流CACRXRX
| Q1 26 | — | — | ||
| Q4 25 | $58.2M | $-47.3M | ||
| Q3 25 | $35.4M | $-117.6M | ||
| Q2 25 | $4.5M | $-79.6M | ||
| Q1 25 | $-727.0K | $-133.8M | ||
| Q4 24 | $55.4M | $-116.7M | ||
| Q3 24 | $-16.2M | $-63.8M | ||
| Q2 24 | $13.2M | $-83.4M |
自由现金流率CACRXRX
| Q1 26 | — | — | ||
| Q4 25 | 85.5% | -133.1% | ||
| Q3 25 | 54.1% | -2272.5% | ||
| Q2 25 | 7.3% | -413.9% | ||
| Q1 25 | -1.2% | -907.4% | ||
| Q4 24 | 116.4% | -2567.7% | ||
| Q3 24 | -36.0% | -244.6% | ||
| Q2 24 | 30.8% | -578.5% |
资本支出强度CACRXRX
| Q1 26 | — | — | ||
| Q4 25 | 8.4% | 3.5% | ||
| Q3 25 | 1.1% | 4.7% | ||
| Q2 25 | 2.4% | 16.4% | ||
| Q1 25 | 2.9% | 12.4% | ||
| Q4 24 | 11.7% | 28.6% | ||
| Q3 24 | 3.8% | 17.5% | ||
| Q2 24 | 3.0% | 8.2% |
现金转化率CACRXRX
| Q1 26 | — | — | ||
| Q4 25 | 2.83× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | 4.15× | — | ||
| Q3 24 | -1.11× | — | ||
| Q2 24 | 1.21× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CAC
| Net Interest Income | $52.4M | 81% |
| Noninterest Income | $12.0M | 19% |
RXRX
暂无分部数据
